This year’s ISPE Biopharmaceutical Manufacturing Conference promises to deliver excellent content and is a must attend for anyone involved in the manufacture of biotech drugs in today’s fast changing environment. Building on the success of our previous conferences this ISPE signature event will cover every aspect from quality, regulatory, drug substance, to drug product, with an emphasis on advanced therapeutic medicinal products including CAR-T, cell and gene therapy, and personalized cancer vaccines. This conference will cover the waterfront from personalized medicines, oligonucleotides, and emerging technologies including continuous manufacturing.
Speakers include industry leaders in manufacturing, quality, regulatory, and academia. This includes prominent FDA speakers from both CBER and CDER. Presentations will be followed by interactive discussions on the challenges and opportunities in truly producing personalized medicines - one patient, one product, covering:
The pharma industry is already under transformation and much more is on the way. Whether you are in a small or large company, start-up or major biopharmaceutical manufacturer, are new or very experienced in the industry, this conference is necessary for you to attend to keep pace with the advancements the industry is bringing in manufacturing technology, newer products, and ultimately patient treatments.
Unlike other Biopharmaceutical manufacturing conferences you may have attended, this conference has a faculty bringing scientific, manufacturing, academic, and health authority experience, and is backed by ISPE’s body of knowledge represented by our expert committees and publications including our Baseline Guides and Good Practice Guides.
There is still time to register however it is getting close so reserve your spot now. If you were waiting for a special invitation, this is it!
The importance of the 2024 ISPE Europe Annual Conference is evident with the continuous challenges the pharmaceutical industry is facing in terms of drug shortages, regulatory requirements, digitalization, automation, and big data management.
It is an exciting time in life sciences. Many companies have focused initial artificial intelligence/machine learning (AI/ML) adoption efforts on developing and implementing ML trained algorithms, which necessitate following a controlled approach such as the GAMP® 5 ML Sub-System methodology shown below. This blog highlights key artifacts and considerations when implementing AI/ML for GxP use...
At the 2023 ISPE Pharma 4.0™ and Annex 1 Conference, held 11 – 12 December 2023 in Barcelona, Spain, a panel discussion that included regulators from around the world, as well as industry experts,...